Recent Additions
Drs. Zhiqiang An and Kyoji Tsuchikama from the McGovern Medical School’s Institute of Molecular Medicine, have developed dual payload antibody-drug conjugates for targeted cancer therapy. These technologies alongside a novel TROP2 antibody, were licensed to a new startup portfolio company, CrossBridge Bio, Inc., with investment in part from TMC Ventures and Portal Innovations.
A machine leaning healthcare company, Cognome is based on former McWilliam's School of Bioinformatics faculty member Dr. Parsa Mirhaji's technology that delivers a unified platform for providers of healthcare to drive continuous healthcare improvement by integrating data, AI/ML models, and governance across networks of Learning Health Systems.
QuizToo, Inc. markets a subscription based learning platform built for organizations to effectively scale impact through learner engagement. Based on the works by Dr. Toufeeq Syed at McWilliams School of Biomedical Informatics, QuizToo allows educators to monetize their expertise and optimize engagement with AI-powered content creation and analytics tools..
Ascential Nutrition LLC is a new supplement company using novel delivery systems for hard-to-absorb natural dietary compounds, based on the work of McGovern Medical School’s Dr. Brijesh S. Gill. Utilizing patent-pending clear advantage nano-emulsion technology, active ingredients remain longer in the bloodstream with an increased bioavailability and adsorption compared to standard supplements.
Incendia Therapeutics is a clinical-stage biotechnology company discovering and developing novel monoclonal antibody therapies that disrupt the tumor microenvironment (TME) to improve outcomes in cancer treatment based on antibody assets developed by McGivern Medical School's and Texas Therapeutics Institute's Dr. Zhiqiang An.
Amprion Inc. develops and markets biomarker tests based on the seed amplification assays (SAA) methodology developed by Dr. Claudio Soto and colleagues at the McGovern Medical School. These tests can aid physicians in diagnosing Parkinson’s, Lewy body dementia, and other neurological diseases, further accelerating precision medicine with the aim of identifying novel drug candidates and underlying pathologies.
A biopharmaceutical company focused on developing innovative therapeutic antibodies for cancer treatment. The Company is applying the latest scientific insights and expertise in drug development to advance novel immuno-oncology products and bring new treatment options to cancer patients, including technology developed in part in the laboratory of UTHealth Houston’s Dr. Zhiqiang An.
Other Selected UTHealth Houston Portfolio Companies
